Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frederick Sabido

Surgery Fort Lee, NJ Medical Doctor

NPI 1811992308 CMS profile 263728

1608 Lemoine Ave, Ste 101, Fort Lee, NJ 07024

Open in the dashboard

General payments

$63,617

96 records reported · program years 2019–2025

Research payments

$27,450

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frederick Sabido of Fort Lee, NJ is reported in the CMS Open Payments database as having received $63,617 across 96 general payments and $27,450 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,829 6
2024 General $20,342 32
2023 General $9,690 15
2022 General $5,728 10
2021 General $4,658 7
2021 Research $22,450 1
2020 General $4,624 9
2020 Research $5,000 1
2019 General $13,746 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frederick Sabido
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Frederick Sabido were reported at $4,829. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Frederick Sabido Surgery median Middle half National median
2019 $13,746 $253 $82–$1,521 $163
2020 $4,624 $131 $40–$706 $114
2021 $4,658 $168 $50–$904 $132
2022 $5,728 $224 $76–$1,218 $149
2023 $9,690 $253 $82–$1,255 $160
2024 $20,342 $279 $90–$1,381 $164
2025 $4,829 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $63,060 84 payments
  2. Medtronic, Inc. $367 4 payments
  3. CONMED Corporation $80 2 payments
  4. Integra LifeSciences Corporation $25 1 payment
  5. Becton, Dickinson and Company $23 1 payment
  6. Clarus Therapeutics Inc. $21 1 payment
  7. Laborie Medical Technologies Corp. $20 1 payment
  8. Ethicon US, LLC $12 1 payment
  9. Surgical Specialties Corporation (US), Inc. $9 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $52,238 15 payments
  2. Travel and Lodging $8,611 38 payments
  3. Food and Beverage $2,768 43 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $63,060 84 payments
  2. INTERSTIM $367 4 payments
  3. AirSeal General Surgery $56 1 payment
  4. SURGIMEND $25 1 payment
  5. AIRSEAL General Surgery $24 1 payment
  6. Phasix Mesh $23 1 payment
  7. JATENZO testosterone replacement therapy $21 1 payment
  8. JATENZO testosterone replacement therapy $21 1 payment
  9. JATENZO testosterone replacement therapy $21 1 payment
  10. alpHaONE $20 1 payment
  11. Other $34 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Davol Inc. $27,450 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

28

Median for General Surgery: 59

Drug cost

$155

Median for General Surgery: $393

Branded share of claims

0%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Anastrozole Generic 16 $99
Mupirocin Generic 12 $55

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$409,973

Of which drugs: $20,260

Medicare patients

210

Average age 66

Services billed

1,085,094

32 women, 178 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 57%
Diabetes 39%
Ischemic heart disease 32%
Depression 20%
Chronic kidney disease 14%
Cancer 11%
Atrial fibrillation 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, testosterone cypionate, 1 mg J1071 Office 151 1,077,824 $20,263

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record